View AllPharmaBiotechMedical
20 March 2019
Medical Devices and No-Deal Brexit: where are we now?

Following our earlier article on the subject, this article sets out the salient features of the...

12 February 2019
Another step in the digital direction: NICE releases Evidence Standards Framework for Digital Health Technologies

As with traditional healthcare products, digital health technologies (DHTs) need to be clinically effective and...

11 February 2019
New guidance on the use of personal data in clinical trials

Following the implementation of the EU General Data Protection Regulation (GDPR), there has been concern...

8 February 2019
The General Court’s judgment in Krka – some welcome clarity over licensing in the context of patent settlements

We reported on this blog about the General Court (GC)’s judgment in Servier on the day on...

31 January 2019
Record investment in UK biotech

The UK’s BioIndustry Association (BIA), together with Informa Pharma Intelligence, have recently published figures which reveal that...

28 January 2019
10 January 2019
CRISPR gene editing technology and its many applications

The revolutionary CRISPR-Cas9 gene editing technology is regularly in the headlines, much of the time...

8 January 2019
A brief history of UCART-19

The rapid development of the immunotherapy landscape has driven increased numbers of acquisitions and collaborations...

12 December 2018
Partial annulment of Servier decision by the General Court – some good news for pharma innovators at last

The General Court has today handed down its judgment in the long-running Servier patent settlement case. 

11 December 2018
New EU Regulation for Veterinary Medicinal Products

The European Council has approved the text for a new Regulation that will overhaul the...

5 December 2018
What is the best response to higher prices in the pharma sector?

The European Commission published a Draft Withdrawal Agreement (the Agreement) on 19 March 2018. The Agreement...

23 November 2018
CAR-T round-up: off-the-shelf challengers and avoiding the (cytokine) storm

It has been another busy period for CAR-T therapies.